Eintrag weiter verarbeiten
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Gespeichert in:
| Zeitschriftentitel: | Vascular Medicine |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Vascular Medicine, 12, 2007, 4, S. 311-318 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
SAGE Publications
|
| Schlagwörter: |
| author_facet |
Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. |
|---|---|
| author |
Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. |
| spellingShingle |
Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. Vascular Medicine Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Cardiology and Cardiovascular Medicine |
| author_sort |
kelly, aaron s. |
| spelling |
Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. 1358-863X 1477-0377 SAGE Publications Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1177/1358863x07084200 <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p> Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vascular Medicine |
| doi_str_mv |
10.1177/1358863x07084200 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xMzU4ODYzeDA3MDg0MjAw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xMzU4ODYzeDA3MDg0MjAw |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
SAGE Publications, 2007 |
| imprint_str_mv |
SAGE Publications, 2007 |
| issn |
1358-863X 1477-0377 |
| issn_str_mv |
1358-863X 1477-0377 |
| language |
English |
| mega_collection |
SAGE Publications (CrossRef) |
| match_str |
kelly2007rosiglitazoneimprovesendothelialfunctionandinflammationbutnotasymmetricdimethylarginineoroxidativestressinpatientswithtype2diabetesmellitus |
| publishDateSort |
2007 |
| publisher |
SAGE Publications |
| recordtype |
ai |
| record_format |
ai |
| series |
Vascular Medicine |
| source_id |
49 |
| title |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_unstemmed |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_full |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_fullStr |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_full_unstemmed |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_short |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_sort |
rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| topic |
Cardiology and Cardiovascular Medicine |
| url |
http://dx.doi.org/10.1177/1358863x07084200 |
| publishDate |
2007 |
| physical |
311-318 |
| description |
<jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p> |
| container_issue |
4 |
| container_start_page |
311 |
| container_title |
Vascular Medicine |
| container_volume |
12 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344617633447941 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:09:59.057Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Rosiglitazone+improves+endothelial+function+and+inflammation+but+not+asymmetric+dimethylarginine+or+oxidative+stress+in+patients+with+type+2+diabetes+mellitus&rft.date=2007-11-01&genre=article&issn=1477-0377&volume=12&issue=4&spage=311&epage=318&pages=311-318&jtitle=Vascular+Medicine&atitle=Rosiglitazone+improves+endothelial+function+and+inflammation+but+not+asymmetric+dimethylarginine+or+oxidative+stress+in+patients+with+type+2+diabetes+mellitus&aulast=Bank&aufirst=Alan+J.&rft_id=info%3Adoi%2F10.1177%2F1358863x07084200&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344617633447941 |
| author | Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J. |
| author_facet | Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J., Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J. |
| author_sort | kelly, aaron s. |
| container_issue | 4 |
| container_start_page | 311 |
| container_title | Vascular Medicine |
| container_volume | 12 |
| description | <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p> |
| doi_str_mv | 10.1177/1358863x07084200 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xMzU4ODYzeDA3MDg0MjAw |
| imprint | SAGE Publications, 2007 |
| imprint_str_mv | SAGE Publications, 2007 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1358-863X, 1477-0377 |
| issn_str_mv | 1358-863X, 1477-0377 |
| language | English |
| last_indexed | 2024-03-01T17:09:59.057Z |
| match_str | kelly2007rosiglitazoneimprovesendothelialfunctionandinflammationbutnotasymmetricdimethylarginineoroxidativestressinpatientswithtype2diabetesmellitus |
| mega_collection | SAGE Publications (CrossRef) |
| physical | 311-318 |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | SAGE Publications |
| record_format | ai |
| recordtype | ai |
| series | Vascular Medicine |
| source_id | 49 |
| spelling | Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. 1358-863X 1477-0377 SAGE Publications Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1177/1358863x07084200 <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p> Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vascular Medicine |
| spellingShingle | Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J., Vascular Medicine, Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus, Cardiology and Cardiovascular Medicine |
| title | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_full | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_fullStr | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_full_unstemmed | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_short | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_sort | rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| title_unstemmed | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus |
| topic | Cardiology and Cardiovascular Medicine |
| url | http://dx.doi.org/10.1177/1358863x07084200 |